Is DRREDDY's share going to split?
There have been no new stock split announcements for Dr. Reddy's Laboratories in 2026. The company’s most recent major corporate action regarding its equity shares occurred in October 2024, when it completed a sub-division (split) of its shares from a face value of ₹5 per share to ₹1 per share.
Related FAQs
Based on salary data for 2026, employees at dsm-firmenich in India earn an average of approximately ₹47.0 lakhs per year. Salaries for the profiles reported generally range between ₹46.8 lakhs and ₹47.
Realtek Semiconductor Corporation operates as a fabless semiconductor design enterprise, generating its substantial revenue primarily through the conception, development, and global marketing of integrated circuits.
The name Eisai—referring to the major multinational Japanese pharmaceutical corporation—is correctly pronounced in standard Japanese as /eː.sa.i/, or roughly "eh-sah-ee".
The cost of "really good" or high-quality health insurance varies dramatically depending on the plan tier (Gold vs. Platinum), individual demographics (age, location), and whether the coverage is employer-sponsored or purchased individually.
Dr. Reddy's Laboratories is widely considered a trusted pharmaceutical brand with a strong international reputation.
Dr. Reddy's Laboratories is currently analyzed as having strong fundamentals, with valuation estimates suggesting it is fairly valued as of late July 2026.
Dr. Reddy's Laboratories Ltd is a leading, globally recognized Indian pharmaceutical company.
No, Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company with its headquarters in Hyderabad, India. While it maintains a significant operational and commercial presence in the United States—including a U.S.
As of July 2026, analysis of Dr. Reddy's Laboratories' stock based on Price-to-Earnings (PE) ratios indicates that it is currently overvalued compared to its historical 5-year average PE.